SLRN (Acelyrin Inc.) Net Profit

Acelyrin, Inc. (SLRN) develops advanced treatments for severe inflammation, leveraging patent protection and successful trials. The high selectivity of their drugs allows for the effective suppression of joint and skin disease foci. The biotech company is currently developing its core product using its own capital reserves. The company's commercial performance on this chart demonstrates revenue dynamics, where -0.27 reflects the latest metric value.

SLRN (ACELYRIN) Company Net Income history from 02/21/2024 to 05/31/2025

Financial and market metric breakdowns for ACELYRIN (SLRN)

- price and consensus price forecast:
Stock Quotes ACELYRIN Inc.|SLRN - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization ACELYRIN Inc.|SLRN - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share ACELYRIN|SLRN - Company Book Value|Market-to-Book Ratio acelyrin.com|SLRN - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Acelyrin, Inc.|SLRN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Acelyrin Inc.|SLRN - Company Aggregate Debts|Debts to Book Value ACELYRIN Inc.|SLRN - Company Long-Term Debt|Company Short-Term Loans and Borrowings ACELYRIN|Quick Ratio acelyrin.com
- net income and valuation multiples indicators:
SLRN - Net Profit
Fundamental valuation:SLRN ACELYRIN Inc.

This indicator measures the business's net financial return in real time, allowing investors to identify operational disruptions or market anomalies without the influence of seasonality. When analyzing the financial results of Acelyrin, Inc. (SLRN), it should be noted that profit dynamics correlate directly with the success of isokibep trials and the ability to secure funding for the final stage of the drug's development.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Net Profit TBPH (Theravance Biopharma, Inc.)|Net Profit Aquestive Therapeutics Inc AQST|scPharma - Net Profit|Tectonic Therapeutic, Inc. (TECX) - Net Income|TNXP: Net Profit|Company Net Income China SXT Pharmaceuticals, Inc. (SXTC)|Company Net Income Eupraxia Pharmaceuticals, Inc.|Company Net Income BHST|Net Income EXOZ (Invizyne Technologies, Inc.)|ORMP - Company Net Income|Company Net Income Entera Bio ENTX|Final Profit HYFT|ABVC BioPharma, Inc. - Net Profit|Net Financial Result Cumberland Pharmaceuticals Inc CPIX|Quantum BioPharma Limited (QNTM) - Company Net Income|Company Profit FGEN|Net Income TELO|RANI: Final Profit|Net Profit SNYR|Net Financial Result rallybio.com|Company Net Income Lexaria Bioscience Corp. LEXX|PULM: Company Profit|Pheton - Net Profit|Aptorum Group Limited (APM) - Net Income|LYRA (Lyra Therapeutics) - Net Income|IBO - Net Financial Result|Company Net Income TNF Pharmaceuticals Inc.|cbdMD Corp (YCBD) - Net Financial Result|Company Net Income PainReform Ltd. (PRFX)|Company Net Income CYTO (altamiratherapeutics.com)|Company Net Income Lipella Pharmaceuticals, Inc. LIPO|Final Profit OPTN|PIRS - Company Net Income|PROC (Procaps Group Corp) - Company Profit|Petros Pharmaceuticals (PTPI) - Company Net Income|Profit After Tax QLI (qlsyy.net)|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit